Becton, Dickinson, and Company: Will Its AI & Data-Driven Innovation Be A Breakthrough Move?

Becton, Dickinson and Company (BD) recently reported its financial results for the fourth quarter and the full year of fiscal 2024. The results presented a mixed picture of growth, strategic challenges, and operational efficiency, showcasing both accomplishments and hurdles the company faced during the period. On the positive side, BD reported a robust growth in its revenues, with total revenue for the fourth quarter increasing by 7.4% to reach $22.1 billion. Organic growth was recorded at 6.2%, reflecting the company’s capacity to generate solid growth despite global challenges. This growth was primarily driven by the strong performance in the MedTech and Diagnostics segments, which grew by 5.9% throughout the year. In particular, the recently relaunched BD Alaris infusion system significantly contributed to the fourth quarter results, marking the company’s first year back to historical run rates since relaunch. The company also benefited from the acquisition of Edwards Critical Care, now integrated as Advanced Patient Monitoring, and achieved a $74 million revenue contribution.